291 related articles for article (PubMed ID: 28157097)
1. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
Matsunaga S; Kishi T; Iwata N
J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
[TBL] [Abstract][Full Text] [Related]
2. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
3. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators.
Yasue I; Matsunaga S; Kishi T; Fujita K; Iwata N
J Alzheimers Dis; 2016; 50(3):733-40. PubMed ID: 26757194
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Aboulatta L; Haidar L; Abou-Setta A; Askin N; Rabbani R; Lavu A; Peymani P; Zarychanski R; Eltonsy S
CNS Drugs; 2023 Nov; 37(11):941-956. PubMed ID: 37973769
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
6. Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
Murata M; Hasegawa K; Kanazawa I; Fukasaka J; Kochi K; Shimazu R;
Mov Disord; 2015 Sep; 30(10):1343-50. PubMed ID: 26094993
[TBL] [Abstract][Full Text] [Related]
7. Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials.
Tsuboi Y; Nakamura M; Maruyama H; Matsumoto Y
J Neurol Sci; 2021 Nov; 430():120026. PubMed ID: 34715471
[TBL] [Abstract][Full Text] [Related]
8. Zonisamide: in Parkinson's disease.
Yang LP; Perry CM
CNS Drugs; 2009 Aug; 23(8):703-11. PubMed ID: 19594199
[TBL] [Abstract][Full Text] [Related]
9. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
10. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
Grover ND; Limaye RP; Gokhale DV; Patil TR
Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
[TBL] [Abstract][Full Text] [Related]
11. Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
Giossi R; Carrara F; Mazzari M; Lo Re F; Senatore M; Schicchi A; Corrù F; Fittipaldo VA; Pani A; Tramacere I; Elia AE; Scaglione F
Clin Drug Investig; 2021 Apr; 41(4):321-339. PubMed ID: 33674954
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
[TBL] [Abstract][Full Text] [Related]
13. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson's Disease: a Network Meta-Analysis.
Li BD; Cui JJ; Song J; Qi C; Ma PF; Wang YR; Bai J
Cell Physiol Biochem; 2018; 45(1):119-130. PubMed ID: 29339630
[TBL] [Abstract][Full Text] [Related]
15. Zonisamide has beneficial effects on Parkinson's disease patients.
Murata M; Horiuchi E; Kanazawa I
Neurosci Res; 2001 Dec; 41(4):397-9. PubMed ID: 11755227
[TBL] [Abstract][Full Text] [Related]
16. Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review.
Kong L; Xi J; Jiang Z; Yu X; Liu H; Wang Z
Biomed Res Int; 2022; 2022():4817488. PubMed ID: 36132085
[TBL] [Abstract][Full Text] [Related]
17. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
Shen T; Ye R; Zhang B
Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E; Stern MB
Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
[TBL] [Abstract][Full Text] [Related]
20. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
Murata M; Hasegawa K; Kanazawa I;
Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
